Strand Therapeutics focuses on the development of programmable, long-acting mRNA therapeutics within the biotechnology sector. The company offers a platform for creating mRNA drugs that are designed to deliver precise, multi-functional, and potentially curative treatments by programming logic-based circuits into mRNA to control protein expression in targeted cells. Strand Therapeutics' products are primarily aimed at improving treatment options for cancer and other life-threatening diseases. It was founded in 2017 and is based in Boston, Massachusetts.

VaxEquity develops RNA-based therapeutics and vaccines designed to meet medical needs. It specializes in amplifying the impact of RNA vaccines and therapeutics by using its self-amplifying RNA platform and provides better protein expression. The company was founded in 2020 and is based in Cambridge, U.K.

Harness Therapeutics operates as a biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases. The company specializes in messenger ribonucleic acid (mRNA)-targeted oligonucleotide-based methodologies to increase protein levels in a controlled manner. It aims to transform the treatment of conditions such as Alzheimer's, Parkinson's, and Huntington's disease. Harness Therapeutics primarily serves the healthcare sector. It was formerly known as Transine Therapeutics. Harness Therapeutics was founded in 2018 and is based in Cambridge, United Kingdom.

Sapreme Technologies is a preclinical-stage biotech company focused on developing RNA therapeutics for genetically driven diseases. The company's main offerings include endosomal escape technology that facilitates the delivery of large molecules such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) to intracellular targets in various tissues, including the liver, muscle, heart, kidney, and brain. Sapreme's technology platform aims to improve receptor-targeted delivery and endosomal release of therapeutics in conditions like neuromuscular, renal, and cardiometabolic diseases. It was founded in 2016 and is based in Utrecht, Netherlands.

Cook MyoSite specializes in regenerative medicine within the biotechnology sector, focusing on advancing personalized investigational cell therapy products. The company offers specialized treatments that utilize a patient's own muscle cells, currently under clinical trial investigation. Cook MyoSite primarily serves sectors involved in clinical research and regenerative medical applications. It was founded in 2002 and is based in Pittsburgh, Pennsylvania.

Versameb is a biotechnology company focused on the discovery and development of RNA-based drugs. The company provides solutions for modulating protein expression and influencing therapeutic targets using a molecular construct. Versameb's VERSagile technology platform supports the application of functional RNA in different disease contexts, with the goal of expanding the use of RNA therapeutics. It was founded in 2017 and is based in Basel, Switzerland.